Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies.

MLA

Panaccione, Remo, et al. “Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn’s Disease Studies.” Journal of Crohn’s & Colitis, vol. 13, no. 6, May 2019, pp. 725–34. EBSCOhost, https://doi.org/10.1093/ecco-jcc/jjy223.

APA

Panaccione, R., Löfberg, R., Rutgeerts, P., Sandborn, W. J., Schreiber, S., Berg, S., Maa, J.-F., Petersson, J., Robinson, A. M., & Colombel, J.-F. (2019). Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn’s Disease Studies. Journal of Crohn’s & Colitis, 13(6), 725–734. https://doi.org/10.1093/ecco-jcc/jjy223

Chicago

Panaccione, Remo, Robert Löfberg, Paul Rutgeerts, William J Sandborn, Stefan Schreiber, Sofie Berg, Jen-Fue Maa, Joel Petersson, Anne M Robinson, and Jean-Frederic Colombel. 2019. “Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn’s Disease Studies.” Journal of Crohn’s & Colitis 13 (6): 725–34. doi:10.1093/ecco-jcc/jjy223.